In the emerging field of MRI in prostate cancer (PCa) diagnosis, it has become clear that targeted biopsy with MRI guidance has additional value over systematic transrectal ultrasound-guided biopsies (TRUS-Bx) alone. The targeted biopsy approach driven by a positive MRI increases the diagnostic yield of high-grade [Gleason score (GS) ≥3+4] or clinically significant (cs) PCa, while concomitantly reducing the number of biopsy cores and the detection of low-grade PCa (GS 3+3) (1-3). Consequently, the question arises what the diagnostic accuracy of MRI (with or without targeted biopsies) in current clinical practice would be?

Additional Metadata
Persistent URL dx.doi.org/10.21037/tau.2017.04.35, hdl.handle.net/1765/100685
Journal Translational Andrology and Urology
Citation
Schoots, I.G, & Roobol-Bouts, M.J. (2017). From PROMIS to PRO-MRI in primary prostate cancer diagnosis. Translational Andrology and Urology, 6(3), 604–607. doi:10.21037/tau.2017.04.35